| dbo:abstract | - Lubazodone (developmental code names YM-992, YM-35995) is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed. It acts as a serotonin reuptake inhibitor (Ki for SERT = 21 nM) and 5-HT2A receptor antagonist (Ki = 86 nM), and hence has the profile of a serotonin antagonist and reuptake inhibitor (SARI). The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the α1-adrenergic receptor (Ki = 200 nM) and the 5-HT2C receptor (Ki = 680 nM). Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI. It reached phase II clinical trials for depression, but development was discontinued in 2001 reportedly due to the "erosion of the SSRI market in the United States". (en)
|
| dbo:casNumber | |
| dbo:fdaUniiCode | |
| dbo:pubchem | |
| dbo:thumbnail | |
| dbo:wikiPageExternalLink | |
| dbo:wikiPageID | |
| dbo:wikiPageLength | - 4733 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID | |
| dbo:wikiPageWikiLink | |
| dbp:atcPrefix | |
| dbp:c | |
| dbp:casNumber | |
| dbp:chemspiderid | |
| dbp:f | |
| dbp:h | |
| dbp:iupacName | |
| dbp:n | |
| dbp:o | |
| dbp:pubchem | |
| dbp:routesOfAdministration | |
| dbp:smiles | - C1CC2=COC[C@@H]3CNCCO3 (en)
|
| dbp:stdinchi | |
| dbp:stdinchikey | - HTODIQZHVCHVGM-JTQLQIEISA-N (en)
|
| dbp:synonyms | |
| dbp:unii | |
| dbp:verifiedfields | |
| dbp:verifiedrevid | |
| dbp:width | |
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type | |
| rdfs:comment | - Lubazodone (developmental code names YM-992, YM-35995) is an experimental antidepressant which was under development by Yamanouchi for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed. It acts as a serotonin reuptake inhibitor (Ki for SERT = 21 nM) and 5-HT2A receptor antagonist (Ki = 86 nM), and hence has the profile of a serotonin antagonist and reuptake inhibitor (SARI). The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the α1-adrenergic receptor (Ki = 200 nM) and the 5-HT2C receptor (Ki = 680 nM). Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT2A receptor antagonist in comparison to t (en)
|
| rdfs:label | |
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| isdbo:wikiPageWikiLink of | |
| isfoaf:primaryTopic of | |
